Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Levamisole treatment for children with steroid sensitive nephrotic syndrome.

- candidate number5633
- NTR NumberNTR1769
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR20-apr-2009
- Secondary IDs2005-005745-18 EudraCT
- Public TitleLevamisole treatment for children with steroid sensitive nephrotic syndrome.
- Scientific TitleLevamisole treatment for children with steroid sensitive nephrotic syndrome. A multicentre, double-blind, placebo-controlled, randomised trial.
- ACRONYMLevamisole trial
- hypothesisThis international, multi-centre, double blinded, placebo-controlled, randomised clinical trial will be performed:
To assess the effectiveness of one year of alternate days Levamisole treatment in a dose of 2.5 mg/kg in the prevention of relapses and prolonging time to relapse after cessation of corticosteroids treatment in children with SSNS.
And as secondary analyses:
1. To evaluate whether the effect of Levamisole varies with disease status (steroid dependent vs. frequently relapsing; low vs. high dose steroid dependency);
2. To evaluate whether the effect of Levamisole varies with prior treatment with Cyclophosphamide;
3. To assess the steroid sparing effect of Levamisole treatment as well as the sparing effect of other immunosuppressive drugs (i.e. average amount administered per patient);
4. To determine whether the effectiveness of Levamisole remains constant or wanes over time;
5. To assess the pharmacokinetics of Levamisole in the target population;
6. To assess the safety of treatment with Levamisole.
- Healt Condition(s) or Problem(s) studiedNephrotic syndrome, Idiopathic
- Inclusion criteria1. Primary diagnosis: frequently relapsing idiopathic Steroid Sensitive Nephrotic Syndrome with or without steroid dependency;
2. 2 > Age < 18 years;
3. Written informed consent.
- Exclusion criteria1. Patients previously treated with Levamisole;
2. Patients unresponsive to Cyclosporine or MMF;
3. Nephrotic syndrome due to a specific kidney disease (such as Henoch –Schoenlein purpura, acute infectious glomerulonefritis, Lupus erythematosus or associated with Hepatitis B or C…);
4. Patients presenting with neutropenia, convulsions or with hepatic diseases;
5. Patients with a prolongation of the QTc-time on the surface electrocardiogram;
6. Pregnancy, breast-feeding or planned pregnancy during the study;
7. Participation in another trial.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 23-mei-2007
- planned closingdate23-nov-2013
- Target number of participants100
- Interventions1. Active compound Levamisole Hydrochloride.
Dosage 2,5 mg/kg on alternate days.
Strength 5, 10, 25 and 50 mg.
Dosage form oral tablets, coated and non-dividable for taste-masking.
2. Placebo matching verum.

Study medication:
1. Start: during Prednisone treatment for relapse when patient’s urine is protein free for 3-21 days;
2. Duration: 12 months or until relapse Concomitant medication.
Cyclosporine, Cyclophosphamide, MMF and other immunosuppressive drugs are not permitted.
Prednisone:given at inclusion during relapse in accordance with the French protocol including tapering (Société de Néphrologie Pédiatrique).
Cohort study: To evaluate whether Levamisole effect remains constant or wanes over time and to evaluate side effects of long term Levamisole treatment, Levamisole patients still in remission at trial completion will be followed for another 18 months (12 additional months of levamisole plus 6 extra months after Levamisole cessation).
- Primary outcomeThe primary endpoint is defined as the time to relapse which is the time between start of the study medication and occurrence of a relapse or, in case of no relapse, time of censoring (12 months after start of trial medication). Only a relapse necessitating prednisone treatment is considered a primary endpoint relapse. Proposed end of the blinded part of the study is in all patients 12 months after start of the study medication.
- Secondary outcome1. Average quantity in milligrams of steroids administered per month during the study;
2. Evaluation whether treatment effect differs with underlying disease process (steroid dependency yes/no) and prior use of disease modifying agents (yes/no);
3. Maintenance dose prednisone at time of relapse.
- Timepoints1. 05/2007: start inclusion;
2. 05/2011: end inclusion;
3. 05/2012: end cohort, begin wash out;
4. 11/2012: end wash out;
5. 11/2013: final report.
- Trial web
- statusopen: patient inclusion
- Sponsor/Initiator Academic Medical Center (AMC), Amsterdam
- Funding
(Source(s) of Monetary or Material Support)
Dutch Kidney Foundation (Nierstichting Nederland), Academic Medical Center (AMC), Emma Children's Hospital, Europese Unie (EU), Dutch Orphan Disease Foundation, French ministry of health, ACE Pharmaceuticals
- PublicationsDavin JC, Merkus MP. - Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise? Pediatr Nephrol. 2005 Jan;20(1):10-4.
- Brief summaryAnnually there are about 100 new children with steroid sensitive nephrotic syndrome in The Netherlands. 50-60% relapse as soon as dosage prednison is stopped or decreased. These children are therefore exposed to toxic side effects of long-term steroids. Among the alternatives used for sparing steroids, levamisole is the least toxic and expensive, however, hardly used. Lack of good quality evidence, no approval for this indication, and difficulty to obtain levamisole may be responsible. An adequately designed RCT is now required to determine whether levamisole is effective in children with SSNS.
- Main changes (audit trail)
- RECORD20-apr-2009 - 23-sep-2009

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar